Skip to main content
. 2017 Nov 14;39(1):151–159. doi: 10.3892/or.2017.6097

Figure 2.

Figure 2.

Representative immunostainings of HMGB1 and calreticulin before and after NAC in breast cancer (A) and ESCC (B) cases. Sections in individual samples were observed at a magnification of ×400. HMGB1, high-mobility group box 1 protein; NAC, neoadjuvant chemotherapy; ESCC, esophageal squamous cell carcinoma.